Alphamab Oncology (9966.HK)

HKD 7.85

(21.52%)

Gross Profit Summary of Alphamab Oncology

Alphamab Oncology's latest annual gross profit in 2023 was 163.53 Million CNY , up 33.35% from previous year.
Alphamab Oncology's latest quarterly gross profit in 2024 Q2 was 142.75 Million CNY , down 0.0% from previous quarter.
Alphamab Oncology reported a annual gross profit of 122.63 Million CNY in annual gross profit 2022, down -14.23% from previous year.
Alphamab Oncology reported a annual gross profit of 142.99 Million CNY in annual gross profit 2021, down 0.0% from previous year.
Alphamab Oncology reported a quarterly gross profit of 103.3 Million CNY for 2023 Q2, down 0.0% from previous quarter.
Alphamab Oncology reported a quarterly gross profit of 163.53 Million CNY for 2023 FY, up 33.35% from previous quarter.

Annual Gross Profit Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Gross Profit of Alphamab Oncology (2023 - 2017)

Year	Gross Profit	Gross Profit Growth
2023	163.53 Million CNY	33.35%
2022	122.63 Million CNY	-14.23%
2021	142.99 Million CNY	0.0%
2020	- CNY	-100.0%
2019	4.99 Million CNY	779.18%
2018	-735 Thousand CNY	-160.1%
2017	1.22 Million CNY	0.0%

Year	Gross Profit	Gross Profit Growth
2024 Q2	142.75 Million CNY	0.0%
2023 Q2	103.3 Million CNY	0.0%
2023 FY	163.53 Million CNY	33.35%
2023 Q4	60.23 Million CNY	0.0%
2022 Q4	83.88 Million CNY	0.0%
2022 FY	122.63 Million CNY	-14.23%
2022 Q2	38.74 Million CNY	0.0%
2021 Q2	- CNY	0.0%
2021 Q4	142.99 Million CNY	0.0%
2021 FY	142.99 Million CNY	0.0%
2020 FY	- CNY	-100.0%
2020 Q4	- CNY	0.0%
2020 Q2	- CNY	0.0%
2019 FY	4.99 Million CNY	779.18%
2019 Q4	2.43 Million CNY	0.0%
2019 Q2	2.55 Million CNY	0.0%
2019 Q1	- CNY	100.0%
2018 Q1	- CNY	0.0%
2018 Q2	346 Thousand CNY	0.0%
2018 FY	-735 Thousand CNY	-160.1%
2018 Q4	-1.08 Million CNY	0.0%
2017 Q2	- CNY	0.0%
2017 Q1	- CNY	0.0%
2017 FY	1.22 Million CNY	0.0%
2017 Q4	- CNY	0.0%
2016 Q4	- CNY	0.0%

Peer Gross Profit Comparison of Alphamab Oncology

Name	Gross Profit	Gross Profit Difference
Uni-Bio Science Group Limited	392.81 Million HKD	58.368%
CK Life Sciences Int'l., (Holdings) Inc.	947.7 Million HKD	82.744%